2 weeks Ago By ABMN Staff
Neumora Therapeutics ( NASDAQ:NMRA – Get Free Report ) is one of 296 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Neumora Therapeutics to related companies based on the strength of its earnings, risk, valuation, institutional ownership, dividends, profitability and analyst recommendations. Earnings & Valuation This table compares Neumora Therapeutics and its rivals gross revenue, earnings per share and valuation. Neumora Therapeutics’ rivals have higher revenue and earnings than Neumora Therapeutics.
Neumora Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry. Profitability Analyst Recommendations This is a breakdown of recent ratings and recommmendations for Neumora Therapeutics and its rivals, as provided by MarketBeat. Neumora Therapeutics presently has a consensus target price of $21.
67, indicating a potential upside of 121.77%. As a group, “Biological products, except diagnostic” companies have a potential upside of 63.
12%. Given Neumora Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Neumora Therapeutics is more favorable than its rivals. Insider & Institutional Ownership 47.
7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors.
26.4% of Neumora Therapeutics shares are owned by company insiders. Comparatively, 16.
0% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Risk and Volatility Neumora Therapeutics has a beta of 3.
92, suggesting that its stock price is 292% more volatile than the S&P 500. Comparatively, Neumora Therapeutics’ rivals have a beta of 1.18, suggesting that their average stock price is 18% more volatile than the S&P 500.
Summary Neumora Therapeutics beats its rivals on 7 of the 13 factors compared. Neumora Therapeutics Company Profile ( Get Free Report ) Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases.
The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease.
The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021.
Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts. Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
